Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P78536
UPID:
ADA17_HUMAN
Alternative names:
Snake venom-like protease; TNF-alpha convertase; TNF-alpha-converting enzyme
Alternative UPACC:
P78536; O60226
Background:
Disintegrin and metalloproteinase domain-containing protein 17, also known as TNF-alpha convertase, plays a pivotal role in the cleavage of membrane-bound precursors to their mature soluble forms. It is involved in the release of several cell-surface proteins, including TNF-receptor, interleukin 1 receptor type II, and the amyloid precursor protein. This enzyme is also an activator of the Notch pathway, crucial for cell differentiation.
Therapeutic significance:
The protein's involvement in Inflammatory skin and bowel disease, neonatal, 1, underscores its potential as a therapeutic target. Understanding the role of Disintegrin and metalloproteinase domain-containing protein 17 could open doors to potential therapeutic strategies for managing this disorder.